Atara Biotherapeutics
ATRA
90 hedge funds and large institutions have $612M invested in Atara Biotherapeutics in 2015 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 10 reducing their positions, and 6 closing their positions.
420% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 10
267% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 6
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more funds holding
Funds holding: 74 → 90 (+16)
13% more call options, than puts
Call options by funds: $1.46M | Put options by funds: $1.29M
12% less capital invested
Capital invested by funds: $695M → $612M (-$83.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BAMCO Inc
New York
|
+$37M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
+$33M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.6M |
| 4 |
State Street
Boston,
Massachusetts
|
+$28.4M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$27.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$12.7M |
| 2 |
VAM
Visium Asset Management
New York
|
-$3.52M |
| 3 |
TAM
Tiverton Asset Management
Wilimington,
Delaware
|
-$1.95M |
| 4 |
RFC
Russell Frank Company
Seattle,
Washington
|
-$1.23M |
| 5 |
JP Morgan Chase
New York
|
-$1.2M |
ATRA Hedge Fund Activity: Q3 2015 in Review
90 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q3 2015, worth a combined $612M — down 12% from $695M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ATRA positions and 6 closed out — a net gain of 16 holders — while 52 added to existing stakes and 10 trimmed.
The largest buyer was BAMCO Inc, adding an estimated $37M. The largest seller was EcoR1 Capital, cutting an estimated $12.7M.
- 90 institutional investors held Atara Biotherapeutics (ATRA) as of Q3 2015, up from 74 in Q2 2015.
- Funds reported $612M of Atara Biotherapeutics stock for Q3 2015, down 12% quarter-over-quarter.
- 22 funds opened new Atara Biotherapeutics positions in Q3 2015 and 6 closed out, a net change of +16 holders.
- The largest Atara Biotherapeutics buyer in Q3 2015 was BAMCO Inc, an estimated $37M added.
- The largest Atara Biotherapeutics seller in Q3 2015 was EcoR1 Capital, an estimated $12.7M sold.
Based on aggregated 13F filings for Q3 2015.